A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

  • End date
    Jan 1, 2024
  • participants needed
  • sponsor
    Eli Lilly and Company
Updated on 17 September 2022
measurable disease
kidney function tests
neutrophil count
cancer chemotherapy


This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.

Condition Desmoplastic Small Round Cell Tumor
Treatment cyclophosphamide, Vinorelbine, Ramucirumab
Clinical Study IdentifierNCT04145349
SponsorEli Lilly and Company
Last Modified on17 September 2022


Yes No Not Sure

Inclusion Criteria

Participants must have discontinued all previous treatments for cancer or investigational agents ≥7 days after the last dose or per the type of previous treatment as stated in the protocol and must have recovered from the acute effects to ≤Grade 2 for alopecia and decreased tendon reflex and to ≤Grade 1 for all other effects at the time of enrollment, unless otherwise noted. Consult with the Lilly clinical research physician or scientist for the appropriate length of time prior to the first dose of study treatment
Participants with relapsed, recurrent, or refractory DSRCT
Participants must
Have measurable disease by Response Evaluation Criteria in Solid Tumors, Version (RECIST) 1.1
Have received at least one prior line of systemic treatment (including neoadjuvant and adjuvant chemotherapy). This prior treatment must include approved therapies for which they are eligible, unless the participant is not a suitable candidate for the approved therapy
Not be eligible for surgical resection at time of enrollment
Adequate cardiac function, defined as: Shortening fraction of ≥27% by echocardiogram
Adequate blood pressure (BP) control, defined as
or ejection fraction of ≥50% by gated radionuclide study
Participants ≥18 years: Controlled hypertension defined as systolic BP ≤150 millimeters of mercury (mmHg) or diastolic BP ≤90 mmHg where standard medical management is permitted. Please note that ≥2 serial BP readings should be obtained and averaged to determine baseline BP
Adequate hematologic function, as defined as
Participants <18 years: A BP ≤95th percentile for age, height, and gender measured as described in National High Blood Pressure Education Program Working Group (NHBPEPWG) on High Blood Pressure in Children and Adolescents (2004), where standard medical management is permitted. Please note that ≥2 serial BP readings should be obtained and averaged to determine baseline BP
Absolute neutrophil count (ANC): ≥750/microliters (µL) granulocyte-colony stimulating factor (G-CSF) permitted up to 48 hours prior. Participants with documented history of benign ethnic neutropenia or other conditions could be considered with a lower ANC after discussion with and approval from the Lilly clinical research physician or scientist
Platelets: ≥75,000/cubic millimeters. Platelet transfusion permitted up to 72 hours prior
Adequate renal function, as defined as
Hemoglobin: ≥8 grams per deciliter (g/dL) (≥80 g/liter). Transfusions to increase the participant's hemoglobin level to at least 8 g/dL are permitted; however, study treatment must not begin until 7 days after the transfusion, and complete blood count criteria for eligibility are confirmed within 24 hr of first study dose
Creatinine clearance or radioscope glomerular filtration rate (GFR) ≥60 milliliters/minute/meters squared OR serum creatinine meeting the following
for participants <18 years of age, serum creatinine based on age/gender as follows: Age 1 to <2 years maximum serum creatinine 0.6, Age 2 to <6 years maximum serum creatinine 0.8, Age 6 to <10 years maximum serum creatinine 1.0, Age 10 to <13 years maximum serum creatinine 1.2, Age 13 to <16 years maximum serum creatinine 1.5 for males and 1.4 for females, Age 16 to <18 years maximum serum creatinine 1.7 for males and 1.4 for females
for participants ≥18 years of age serum creatinine ≤1.5×upper limit of normal (ULN)
Urine protein meeting the following parameters
for participants ≥18 years of age: <2+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥2+, then a 24-hour urine must be collected and must demonstrate <2 grams of protein in 24 hours to allow participation in the study
for participants <18 years of age: ≤30 milligrams per deciliter urine analysis or <2+ on dipstick. If urine dipstick or routine analysis indicates proteinuria ≥2+, then a 24-hour urine must be collected and must demonstrate <1 g of protein in 24 hours to allow participation in the study
Adequate liver function
Total bilirubin: ≤1.5×ULN. Except participants with document history of Gilbert Syndrome who must have a total bilirubin level of <3.0×ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): ≤2.5×ULN OR ≤5.0×ULN if the liver has tumor involvement
The participant has an adequate coagulation function as defined by International
Female participants of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to randomization. Male and female participants must agree to use highly effective contraception for the duration of the study and up to 3 months following the last dose of ramucirumab and vinorelbine, and 12 months following the last dose of cyclophosphamide in order to prevent pregnancy
Normalized Ratio ≤1.5 or prothrombin time ≤1.5×ULN, and partial thromboplastin
time ≤1.5×ULN if not receiving anticoagulation therapy. For participants
receiving anticoagulants, exceptions to these coagulation parameters are
allowed if they are within the intended or expected range for their
therapeutic use. Participants must have no history of clinically significant
active bleeding (defined as within 14 days of first dose of study drug) or
pathological condition that carries a high risk of bleeding (for example
tumor involving major vessels or known esophageal varices)
The participant has adequate hematologic and organ function ≤1 week (7 days) prior to first dose of study drug

Exclusion Criteria

Participants with severe and/or uncontrolled concurrent medical disease or psychiatric illness/social situation that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
Participants who have active infections requiring therapy
Participants with an active fungal, bacterial, and/or known severe viral infection including, but not limited to, human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required)
Surgery: Participants who have had, or are planning to have, the following invasive procedures are not eligible
Major surgical procedure, laparoscopic procedure, or significant traumatic injury within 28 days prior to enrollment
Central line placement or subcutaneous port placement is not considered major surgery
Core biopsy, fine needle aspirate, and bone marrow biopsy/aspirate are not considered major surgeries
Surgical or other wounds must be adequately healed prior to enrollment
Bleeding and thrombosis
Participants with a bleeding diathesis or vasculitis are not eligible
Participants who have had allogeneic bone marrow or solid organ transplant are
Participants with known or prior history in the prior 3 months of esophageal varices are not eligible
Participants with a history of deep vein thrombosis requiring medical intervention (including pulmonary embolism) within 3 months prior to study enrollment are not eligible
Participants with a history of hemoptysis or other signs of pulmonary hemorrhage within 3 months prior to study enrollment are not eligible
Participants with a history of central nervous system (CNS) arterial/venous thromboembolic events (VTEs) including transient ischemic attack (TIA) or cerebrovascular accident (CVA) within 6 months prior to study enrollment are not eligible
Participants with myocardial infarction or unstable angina within the prior 6 months
Participants with New York Heart Association Grade 2 or greater congestive heart failure (CHF)
Participants with serious and inadequately controlled cardiac arrhythmia
Participants with evidence of active bleeding or a history of significant (≥Grade 3) bleeding event within 3 months prior to enrollment are not eligible
Participants with significant vascular disease (eg, aortic aneurysm, history of aortic dissection)
Participants with clinically significant peripheral vascular disease
Participants with a history of hypertensive crisis or hypertensive encephalopathy within 6 months of study enrollment are not eligible
Participants who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment are not eligible
Participants previously treated and progressed on combination cyclophosphamide and vinorelbine regimen. Participants who received combination as maintenance therapy, without progression, would be eligible
Participants with a known hypersensitivity to ramucirumab, cyclophosphamide, vinorelbine or any of the excipients of the medicinal products
Hepatic impairment
Severe liver cirrhosis Child-Pugh Class B (or worse)
Cirrhosis with a history of hepatic encephalopathy
Clinically meaningful ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis
History of hepatorenal syndrome
Participants who have a history of fistula, gastrointestinal (GI) ulcer or
perforation, or intra-abdominal abscess within 3 months of study enrollment
The participant has a urinary outflow obstruction
are not eligible
The participant has Grade 2 hematuria or non-infectious cystitis at the time of screening
Participants with central nervous system (CNS) involvement are ineligible
The participant has a bowel obstruction, history or presence of inflammatory
enteropathy or extensive intestinal resection (eg, hemicolectomy or extensive
small intestine resection with chronic diarrhea), Crohn's disease, ulcerative
colitis, or chronic diarrhea
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note